CoChat

Molecular Target Class Is Predictive of In vitro Response Profile

Open access
Greshock, Joel, Bachman, Kurtis E., Degenhardt, Yan Y., Jing, Junping, Wen, Yuan H., Eastman, Stephen, McNeil, Elizabeth, Moy, Christopher, Wegrzyn, Ronald, Auger, Kurt, Hardwicke, Mary Ann, Wooster, Richard · 2010 · Cancer Research
Cited by 123

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Preclinical cellular response profiling of tumor models has become a cornerstone in the development of novel cancer therapeutics. As efforts to predict clinical efficacy using cohorts of in vitro tumor models have been successful, expansive panels of tumor-derived cell lines can recapitulate an “all comers” efficacy trial, thereby identifying which tumors are most likely to benefit from treatment. The response profile of a therapy is most often studied in isolation; however, drug treatment effect patterns in tumor models across a diverse panel of compounds can help determine the value of unique molecular target classes in specific tumor cohorts. To this end, a panel of 19 compounds was evaluated against a diverse group of cancer cell lines (n = 311). The primary oncogenic targets were a key determinant of concentration-dependent proliferation response, as a total of five of six, four of four, and five of five phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, insulin-like growth factor-I receptor (IGF-IR), and mitotic inhibitors, respectively, clustered with others of that common target class. In addition, molecular target class was correlated with increased responsiveness in certain histologies. A cohort of PI3K/AKT/mTOR inhibitors was more efficacious in breast cancers compared with other tumor types, whereas IGF-IR inhibitors more selectively inhibited growth in colon cancer lines. Finally, specific phenotypes play an important role in cellular response profiles. For example, luminal breast cancer cells (nine of nine; 100%) segregated from basal cells (six of seven; 86%). The convergence of a common cellular response profile for different molecules targeting the same oncogenic pathway substantiates a rational clinical path for patient populations most likely to benefit from treatment. Cancer Res; 70(9); 3677–86. ©2010 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-09-3788

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 123

Metadata

Authors
Greshock, J., Bachman, K. E., Degenhardt, Y. Y., Jing, J., Wen, Y. H., Eastman, S., McNeil, E., Moy, C., Wegrzyn, R., Auger, K., Hardwicke, M. A., & Wooster, R.
Venue
Cancer Research
Published
2010-04-28
Volume
70
Issue
9
Pages
3677-3686
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2145047343
Cited by
123
References
8
FWCI
3.90
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular Target Class Is Predictive of In vitro Response Profile. https://app.cochat.ai/papers/10.1158/0008-5472.can-09-3788
The paper
Greshock, J., Bachman, K. E., Degenhardt, Y. Y., Jing, J., Wen, Y. H., Eastman, S., McNeil, E., Moy, C., Wegrzyn, R., Auger, K., Hardwicke, M. A., & Wooster, R. (2010). Molecular Target Class Is Predictive of In vitro Response Profile. Cancer Research. https://doi.org/10.1158/0008-5472.can-09-3788

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.